Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
381. |
ECCT/19/04/04 | Effectiveness of an integrated programme to reduce maternal and child malnutrition in Kenya Effectiveness of an integrated programme to reduce maternal and child malnutrition in Kenya:two cluster-randomized controlled trials in pregnant women and their offspring and in 6-59 months old children comparing an agricultural intervention alone with a combined agricultural, nutrition and WASH intervention. |
Principal Investigator(s) 1. Rita Wegmuller Site(s) in Kenya 1. Kakamega and Bungoma (Kakamega county) |
05-07-2019 |
View |
382. |
ECCT/19/04/03 | Phase III pediatric study with the L-PZQ ODTs An Open-label, Phase 3 efficacy and safety study of L-praziquantel orodispersible tablets (L-PZQ ODT) in Schistosoma-infected children 3 months to 6 years of age, including a 2:1 randomized, controlled cohort of Schistosoma mansoni-infected children 4 to 6 years of age treated with L-PZQ ODT or commercial PZQ (Biltricide®) |
Principal Investigator(s) 1. Maurice Reuben Odiere Site(s) in Kenya KEMRI-Centre for Global Health Research (CGHR) |
18-06-2019 |
View |
383. |
ECCT/19/04/02 | NADIA \"Nucleosides And Darunavir/Dolutegravir In Africa\" A randomised controlled trial of darunavir versus dolutegravir and tenofovir versus zidovudine in second-line antiretroviral therapy regimens for the public health approach in sub-Saharan Africa |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya Moi University Clinical Research Centre |
12-08-2019 |
View |
384. |
ECCT/19/04/01 | A study to determine if a new shigella vaccine (Shigella4V) is safe, induces immunity and the best dose among Kenyan infants. Safety and immunogenicity of a Shigella-tetravalent bioconjugate vaccine: A phase 1/2 randomized controlled and age descending study including dose finding in 9-month-old infants |
Principal Investigator(s) 1. Mainga Hamaluba 2. Kosgei Josphat Site(s) in Kenya 1. KEMRI-United States Army Medical Research Unit-Kenya, Kericho (Kericho county) 2. KEMRI Wellcome Trust Research Program-CGMR-C (Kilifi county) |
08-07-2019 |
View |
385. |
ECCT/19/03/05 | EPI-MAL-003 (Siaya) A prospective study to evaluate the safety, effectiveness and impact of the RTS,S/AS01E vaccine in young children in sub-Saharan Africa (v1.0 11Oct2017): Site-specific protocol for Siaya County, western Kenya |
Principal Investigator(s) 1. Simon Kariuki 2. Martina Oneko Site(s) in Kenya 1. Bondo sub-county (Siaya county) 2. Gem sub-county (Siaya county) |
17-05-2019 |
View |
386. |
ECCT/19/03/04 | NIFTY Non-Inferiority Fractional-Doses Trial For Yellow Fever Vaccine |
Principal Investigator(s) 1. George Warimwe Site(s) in Kenya KEMRI Kilifi |
21-06-2019 |
View |
387. |
ECCT/19/03/03 | Biofire FilmArray Gobal Fever GF Panel Clinical Evaluation of the FilmArray Gobal Fever GF Panel |
Principal Investigator(s) 1. JOHN WAITUMBI Site(s) in Kenya KEMRI Walter Reed Project USAMRD A/K Kisumu |
16-05-2019 |
View |
388. |
ECCT/19/03/02 | PREVENT TD A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg daily or 550 mg twice daily) for Chemoprophylaxis Against Travellers’ Diarrhoea (TD) Among Active Duty Deployed U.S. and British Military Personnel (PREVENT TD) |
Principal Investigator(s) 1. Flynn Alexander Site(s) in Kenya Nyati Barracks, British Army Training Unit, Kenya |
10-06-2019 |
View |
389. |
ECCT/19/03/01 | Validation of syringe extension device Validation of re-usable, low cost syringe extension device for the provision of paracervical analgesia during gynecological procedures |
Principal Investigator(s) 1. Stephen Gwer 2. Aparna Ramanathan Site(s) in Kenya 1. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) 2. Kisumu County Hospital (Kisumu county) 3. God\'s Will Clinic (Kisumu county) 4. Marie Stopes Kenya-Kisumu Clinic (Kisumu county) |
01-08-2019 |
View |
390. |
ECCT/19/02/01 | DANCE Study An Open-Label, Single Arm Study to Evaluate the Week 48 Efficacy and Safety of a Two-Drug Regimen of Dolutegravir/Lamivudine (DTG/3TC) as a Fixed Dose Combination (FDC), in Antiretroviral Therapy (ART)-Naive HIV-1-Infected Adolescents, ≥12 To <18 Years of Age who Weigh at Least 40 Kg. |
Principal Investigator(s) 1. Fredrick Odhiambo Otieno 2. Isaac Tsikhutsu Site(s) in Kenya 1. Nyanza Reproductive Health Society (Kisumu county) 2. Kenya Medical Research Institute (Kisumu county) 3. Kenya Medical Research Institute, Walter Reed Project (Kericho county) |
14-08-2019 |
View |